FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

Article Link: FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti (trastuzumab-anns) for all approved indications of the…

Source: FDA New Drug Approvals